Skip to content
Home » AI Medical Service AI Medical Service wins “Innovation Showcase” at “2024 Japan-U.S. Innovation Awards ”

AI Medical Service AI Medical Service wins “Innovation Showcase” at “2024 Japan-U.S. Innovation Awards ”

[AI Medical Service] AI Medical Service received “Innovation” at the “2024 Japan-U.S. Innovation Awards”
Awarded “Showcase”
*AI medical service*
Press release: July 11, 2024
**
AI Medical Service wins “Innovation Showcase” at “2024 Japan-U.S. Innovation Awards”
main banner
AI Medical Service Co., Ltd., which develops endoscope image diagnosis support AI (artificial intelligence) (Head office: Toshima-ku, Tokyo, Representative Director and CEO: Tada)
Tomohiro (hereinafter referred to as “AIM”) is a member of the Japan Society of Northern
California (Northern California Japan Society) and US-Asia Technology at Stanford University
“2024 Japan-U.S.” will be jointly held by Management Center (Stanford University U.S.-Asia Technology Management Research Center). Innovation
The Innovation Awards are given to fast-growing Japanese companies with attractive technology and groundbreaking business ideas that have the potential to have a major impact on the world.
We are pleased to announce that we have won the “Showcase” award.

* ■About “2024 Japan-U.S. Innovation Awards”*
“2024 Japan-U.S. Innovation” will be held for the 14th time this year. The “Emerging Leader Awards” selects one company from startups in Japan and the United States that has made an impact and played an active role in each other’s markets.
(Emerging Leader Award). In addition, five fast-growing companies from Japan with the potential to have a major impact on the world will be named “Innovation”.
This award will be given as a “Showcase” award.
AIM was selected as an innovation showcase company from a total of 60 nominations.

In addition, the 2024 Japan-U.S. Innovation Awards will be held at Stanford University on July 18, 2024 local time.
Symposium Innovation Showcase
In the Presentation section, Kenji Yoshida, AIM’s head of overseas business, will be on stage. In his speech, he will talk about his expectations for AI that supports endoscopic image diagnosis in the medical field and the role that our company will play.

Details of the “2024 Japan-U.S. Innovation Awards” are below: Japan Society of Northern
Please refer to the California website.
https://www.usjinnovate.org/

AIM will continue to accelerate its research and development in order to contribute to the development of endoscopic medicine around the world.

* ■Representative Director and CEO Tomohiro Tada Award-winning comment* I am honored to receive such a wonderful award. Our company is a world leader in endoscopy AI research, and was highly praised for being the world’s first company to utilize AI to promote early detection of gastrointestinal cancer. Additionally, the company already has bases in the United States and Singapore, and has already taken the first step toward overseas expansion in order to achieve its mission of “saving patients around the world.” We were also praised for being recognized as one of the strongest startups in the world.

We will accelerate our research and development in order to deliver endoscopic AI to clinical sites in the United States as soon as possible and contribute to the development of endoscopic medicine in Japan and the United States.

* ■About AI Medical Service*
AIM is a medical AI startup company with the mission of “Saving patients around the world – Zero missed cancers with endoscopic AI”. Japan is at the cutting edge of endoscopic medical care, and has accumulated the world’s highest level of data in terms of quality and quantity. In particular, AIM is conducting joint research and product development with over 100 medical facilities. AIM aims to reduce the number of missed cases of cancer and save patients around the world by quickly delivering endoscopic AI to medical settings.

* ■About Tomohiro Tada, Representative Director and CEO*
Tomohiro Tada
Tomohiro Tada, Doctor of Medicine
[Affiliation/Position]
AI Medical Service Co., Ltd. Representative Director and CEO Chairman of Medical Corporation Tomohiro Gastroenterology and Proctology [Summary]
Graduated from the Department of Medicine, Faculty of Medicine, University of Tokyo in 1996. Worked as a surgical resident at the University of Tokyo Hospital. Completed doctoral course at the University of Tokyo Graduate School of Medicine in 2005. In 2006, he opened Tomohiro Gastroenterology and Proctology. Since 2012, he has been a visiting lecturer at the Department of Oncology Surgery, Faculty of Medicine, University of Tokyo. Established AI Medical Service Co., Ltd. in 2017 and assumed the position of CEO.

* ■Past efforts toward overseas expansion*
Click here for information on our past efforts toward overseas expansion (https://www.ai-ms.com/news/global
) You can check it.

* Company Profile